FDA Sends Interleukin Genetics, DNA-CardioCheck Untitled Letters | GenomeWeb

This article as been updated to note three different tests cited in the FDA's letter and to correctly state that Interleukin's deal with NYU focuses on advancing a test for osteoarthritis progression, not PerioPredict.

NEW YORK (GenomeWeb) – The US Food and Drug Administration has issued untitled letters to Interleukin Genetics and DNA-CardioCheck, requesting additional information on their direct-to-consumer tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.